Given its mechanism of action, rituximab is likely to be effective in patients with IgG4 autoantibody (anti-CNTN1 and anti-NF155)–positive CIDP. Here, CNTN1 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.